



**BIBCOL**

**Bharat Immunologicals & Biologicals Corporation Limited**

CIN – L24232UP1989GOI010542 (A Govt. of India Undertaking)

Regd. Office: Vill. Chola, Bulandshahr(UP)-Pin 203203

Phone 9458096110, Tele Fax -05732 238757

Email – [sklalacs@yahoo.co.in](mailto:sklalacs@yahoo.co.in) Website- [www.bibcol.com](http://www.bibcol.com)

No.BIB/CS/SE/LR-Q3/2017-18

Dated: 22.01.2018

To  
The Listing Agreement  
Bombay Stock Exchange  
Phiroze Jeejeebhoy Towers,  
25, Dalal Street,  
Mumbai – 400 001.

**Ref: Submission of Limited Review Report of the Quarterly Unaudited financial Results for the quarter ended December 2017 under Regulation 33(3)(C ) of LODR**

Sir,

In pursuance of Regulation 33(3) (C ) of the LODR with Stock Exchange, please find enclosed the Limited Review Report along with the financial results for the Quarter ended 31<sup>st</sup> December 2017.

It is requested to kindly take the above on record please.

Thanking you,

Yours truly,

(Sandip Kumar Lal)  
Company Secretary




# Maheshwari P A AND Associates

(Chartered Accountants)

107, 1<sup>st</sup> Floor, Saraswati Plaza, Near NAS College,  
E.K. Road, Meerut

E-Mail: maheshwarica9@gmail.com, No. 0121-4059052

Website: www.maheshwaripaassociates.icai.org.in



## LIMITED REVIEW REPORTS

To

The Board of Directors


M/s Bharat Immunologicals & Biologicals Corporation Limited

We have reviewed the accompanying statement of unaudited financial results of M/s **BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LIMITED** ("the Company") for the period ended December 31<sup>st</sup>, 2017 being submitted by the company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 read with SEBI Circular CIR/CFD/FAC/62/2016 dated July 05, 2016. This statement is the responsibility of the Company's Management and has been approved and prepared by the Board of Directors and in accordance with Indian Accounting Standard (IND- AS) prescribed under section 133 of the Companies Act and read with relevant rules issued thereunder and other accounting principles generally accepted in Indian. Our responsibility is to issue a report on the financial statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results, prepared in accordance with the Indian Accounting Standards as per Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder other recognized accounting practices & policies generally accepted in India, has not disclosed Information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 and SEBI Circular CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed or that it contains any material misstatement.

FOR MAHESHWARI P A AND ASSOCIATES  
(Chartered Accountants)



(PARTNER)

CA. ABHISHEK GOEL

M. NO. 412467

Date: 15/01/ 2018  
Place: Meerut




**BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPN. LTD.**  
Regd. Office: Vill. Chola, Bulandshahr(UP)-203203

**PART I**  
**UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER AND NINE MONTHS ENDED 31.12.2017**  
(Amount Rs. In Lakhs)

	Particulars	3 months ended 31/12/2017	Preceding 3 months ended 30/09/2017	Corresponding 3 months ended in the previous year 31/12/2016	Year to date figures for current period ended 31/12/2017	Previous year ended 31/03/2017
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Income from operations	446.54	30.51	2,404.25	1,311.83	12,418.51
	Other income	35.56	27.02	35.26	89.13	117.68
	<b>Total Revenue (I)</b>	<b>482.10</b>	<b>557.53</b>	<b>2,439.51</b>	<b>1,400.96</b>	<b>12,536.19</b>
2	<b>Expenses</b>					
	(a) Cost of materials consumed	1,805.37	15.31	2,948.64	2,951.07	7,830.32
	(b) Purchases of stock-in-trade	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,695.90)	433.90	(1,252.79)	(2,148.84)	1,913.95
	(d) Employee benefits expense	223.99	224.22	267.02	672.14	1,024.88
	(e) Finance costs	11.27	2.51	114.19	14.44	343.81
	(f) Depreciation and amortization expense	7.20	14.39	1.88	35.98	57.57
	(g) Other expenses	91.97	94.02	203.85	256.35	420.22
	<b>Total Expenses (2)</b>	<b>443.90</b>	<b>784.35</b>	<b>2,282.79</b>	<b>1,781.14</b>	<b>11,590.75</b>
3	<b>Profit/(Loss) before finance cost and exceptional items (1-2)</b>	<b>38.20</b>	<b>(226.82)</b>	<b>156.72</b>	<b>(380.18)</b>	<b>945.44</b>
4	<b>Tax expense</b>					
	(a) Current Tax	-	-	-	-	14.03
	(b) Deferred tax	(11.61)	12.11	(64.03)	6.47	256.90
5	<b>Profit/(Loss) for the period from continuing operations (3-4)</b>	<b>49.81</b>	<b>(238.93)</b>	<b>220.75</b>	<b>(386.65)</b>	<b>674.51</b>
6	Other Comprehensive Incomes, net of income tax	-	-	-	-	-
7	<b>Total Comprehensive Income for the Period (6-7) comprising Profit/(Loss) and other Comprehensive Income for the Period</b>	<b>49.81</b>	<b>(238.93)</b>	<b>220.75</b>	<b>(386.65)</b>	<b>674.51</b>
8	<b>Paid-up equity share capital (Face Value Rs.10)</b>	<b>4,318.00</b>	<b>4,318.00</b>	<b>4,318.00</b>	<b>4,318.00</b>	<b>4,318.00</b>
9	<b>Earnings per share (of Rs. ___/- each) (not annualized):</b>					
	(a) Basic	0.12	(0.55)	0.51	(0.90)	1.56
	(b) Diluted	0.12	(0.55)	0.51	(0.90)	1.56

See accompanying note to the financial results

\* Applicable in the case of consolidated results.







Note: The classification/disclosure of items in the financial results shall be in accordance with the Schedule III. Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details thereof.

PART II

Select Information for the Period Ended 31/12/2017

(Amount Rs. In Lakhs)

	Particulars	3 months ended 31/12/2017	Preceding 3 months ended 30/09/2017	Corresponding 3 months ended in the previous year 31/12/2016	Year to date figures for current period ended 31/12/2017	Previous year ended 31/03/2017
<b>A1</b>	<b>PARTICULARS OF SHAREHOLDING</b>					
	Public shareholding					
	- Number of shares	175,94,000	175,94,000	175,94,000	175,94,000	175,94,000
	- Percentage of shareholding	40.75	40.75	40.75	40.75	40.75
<b>2</b>	Promoters and Promoter Group Shareholding					
	(a) Pledged/Encumbered					
	- Number of shares	-	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-
	(b) Non - encumbered					
	- Number of shares	255,86,000	255,86,000	255,86,000	255,86,000	255,86,000
	- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100.00	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	59.25	59.25	59.25	59.25	59.25
<b>B</b>	Particulars	3 months ended (31/12/2017)				
	<b>INVESTOR COMPLAINTS</b>					
	Pending at the beginning of the quarter.	Nil				
	Received during the quarter.	01				
	Disposed of during the quarter.	01				
	Remaining unresolved at the end of the quarter.	Nil				







SEGMENT REPORTING

	Particulars	3 months ended 31/12/2017	Preceding 3 months ended 30/09/2017	Corresponding 3 months ended in the previous year 31/12/2016	Year to date figures for current period ended 31/12/2017	Previous year ended 31/03/2017
1	<b>SEGMENT REVENUE</b>					
	Oral Polio Vaccine	446.32	529.44	2,403.12	1,309.01	12,415.71
	Zinc Dispersible Tablets	0.22	1.07	1.13	2.82	2.80
	Less : Inter Segment Revenue	-	-	-	-	-
	Net Sales/Income from Operations	446.54	530.51	2,404.25	1,311.83	12,418.51
2	<b>SEGMENT RESULTS (Profit Before Tax)</b>					
	Oral Polio Vaccine	41.03	(224.14)	165.05	(370.92)	983.63
	Zinc Dispersible Tablets	(2.83)	(2.68)	(8.34)	(9.26)	(38.19)
	Less : Other unallocable expenditure net off unallocable income	-	-	-	-	-
	Total Profit Before Tax	38.20	(226.82)	156.71	(380.18)	945.44
3	<b>CAPITAL EMPLOYED (Segment Assets less Liabilities)</b>					
	Oral Polio Vaccine	4,006.28	3,953.64	4,044.40	4,006.28	4,384.18
	Zinc Dispersible Tablets	(205.91)	(203.08)	(196.68)	(205.91)	(205.41)
	Others	-	-	-	-	-
	Total Capital Employed	3,800.37	3,750.56	3,847.72	3,800.37	4,178.77

NOTES :-

- 1 The above Un-Audited results for the Quarter ended 31st December, 2017 have been reviewed by the Audit Committee and were taken on record by the Board of Directors in their respective meetings held on 15th January, 2018.
- 2 This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rule 2015 (Ind AS), prescribed under Section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable. Beginning 1 April 2017, the Company has for the first time adoption Ind AS with a transaction date of 1 April 2016.
- 3 The format for unaudited quarterly results as prescribed in SEBI's Circular CIR/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with requirements of SEBI's Circular dated July 5, 2016, Ind AS and Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with Ind AS.
- 4 The statement does not include Ind AS compliant results for the preceding quarter and previous year ended 31 March, 2017 as the same are not mandatory as per SEBI's Circular dated 5 July 2016.
- 5 Segment information as per Ind AS 108 has been given above as Segment Reporting. The Company is currently engaged in production of Oral Polio Vaccine and Zinc Dispersible Tablets.



*aw* *ay*




- 6 The Ind As complaint corresponding figures in the previous year have not been subjected to review / audited. However , the company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- 7 The reconciliation of net profit or loss reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS as given below:

Description	Corresponding 3 months ended in the previous year 31/12/2016
Net Profit or loss as per previous Indian GAAP	220.75
Change due to implementation of Ind AS	0.00
Net Profit / Loss as per Ind As	220.75

- 8 Previous year/quarter figures have been regrouped/re-arranged wherever necessary, to make it comparable.

Place: New Delhi  
Date : 15.01.2018



(Chandra Prakash Goyal)  
Managing Director

